


Claims 1-16 are pending in this application. Claims 1-16 have been canceled. Claims 17-22 have been added. New claims 17-22 correspond to claims 26-28, 30, 32 and 34 of the Preliminary Amendment to the parent application that was filed on August 13, 1999, which were canceled in response to the Restriction Requirement having a mailing date of September 19, 2001. Upon entry of this Preliminary Amendment, Claims 17-22 will be pending in this application.

Attached hereto as Appendix A captioned "Version with Markings to show changes made" is a marked-up version of the changes made to the claims by the current amendment.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 303-571-4000.

Respectfully submitted,


Don D. Cha
Reg. No. 40,945

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
DDC:mcl
DE 7054007 v1

FOR FILING

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 1, after the TITLE section, the "CROSS-REFERENCE TO RELATED APPLICATION" section has been added as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. Patent Application Serial No. 09/367,459, filed May 8, 2000, which is a national phase of PCT Patent Application No. PCT/AT98/00043, filed February 27 1998, which claims priority to AT Patent Application No. A338/97 filed February 27, 1997, all of which are incorporated herein by reference in their entirety.

IN THE CLAIMS:

Claims 1-16 have been canceled.

New Claims 17-22 have been added as follows:

17. (New) A factor VIII/vWF-complex particularly containing high-molecular vWF multimers, obtainable from a factor VIII/vWF-containing solution by cation exchange chromatography.

18. (New) The factor VIII/vWF-complex of Claim 17, wherein said factor VIII/vWF-complex is particularly free from low-molecular vWF multimers, inactive vWF degradation products, factor VIII free from platelet agglutinating vWF activity and factor VIIIa activity.

19. (New) The factor VIII/vWF-complex of Claim 18, wherein said factor VIII/vWF-complex has a specific vWF activity of at least 66 U/mg protein and a specific factor VIII activity of at least 500 U/mg protein.

20. (New) A preparation comprising factor VIII/vWF-complex of Claim 19, wherein said preparation is virus-safe and free from infectious material.

21. (New) The preparation of Claim 20, wherein said preparation is present in storage-stable form.

22. (New) The preparation of Claim 20, wherein said preparation is formulated as a pharmaceutical preparation.